The maximum plasma levels (~100 nM) and prolonged elimination half-life (>24 h) of Ponatinib in standard of care dose for CML suggest that Ponatinib would be clinically effective for targeting BRAF and ERK signaling inhibition48. This evidence concerns the gene MAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive.